Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 7,864 matching trials from the live ClinicalTrials.gov search.

Filters: Minneapolis, Minnesota Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: exenatide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 60
States / cities: Birmingham, Alabama • Anaheim, California • Bellflower, California + 57 more

Conditions: Brain Tumor, Central Nervous System Tumor, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Liver Cancer, Neuroblastoma, Ototoxicity, Ovarian Cancer, Sarcoma
Interventions: sodium thiosulfate, examination; Drug · Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 18 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2021
U.S. locations: 68
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 61 more

Conditions: Rhinitis, Allergic, Perennial
Interventions: Fluticasone furoate nasal spray, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 12
States / cities: Baltimore, Maryland • Wheaton, Maryland • North Dartmouth, Massachusetts + 9 more

Conditions: Type 1 Diabetes, New Onset
Interventions: Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab; Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 9 Years to 20 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • New Haven, Connecticut + 8 more

Conditions: Carcinoma, Hepatocellular
Interventions: Sorafenib (Nexavar, BAY43-9006), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 18
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 14 more

Conditions: Acute Liver Failure, Fulminant Hepatic Failure, Primary Graft Non-Function, Surgically-Induced Liver Failure
Interventions: ELAD; Biological
Lead sponsor: Vital Therapies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 18
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 14 more

Conditions: Neuropathy, Neuropathy, Diabetic, Neuropathy Toxic
Interventions: Realief Therapy; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: HIV Infections
Interventions: Lamivudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 39
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 27 more

Conditions: Supranuclear Palsy, Progressive
Interventions: BIIB092, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 41 Years to 86 Years
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 33
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 25 more

Conditions: Multiple Myeloma
Interventions: rhIL-2, PNK-007; Drug · Biological
Lead sponsor: Celularity Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: Minneapolis, Minnesota • St Louis, Missouri • Omaha, Nebraska + 4 more

Conditions: Candidiasis, Candidemia
Interventions: Micafungin, Caspofungin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 62
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 49 more

Conditions: Cancer
Interventions: Freenome Test; Diagnostic Test
Lead sponsor: Freenome Holdings Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 7,435 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 68
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Springdale, Arkansas + 62 more

Conditions: HIV Infections, Lipoatrophy
Interventions: NucleomaxX, NucleomaxX placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 20 more

Conditions: Coronary Artery Disease
Interventions: ICD; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 17
States / cities: Anchorage, Alaska • Brandon, Florida • Orlando, Florida + 14 more

Conditions: NASH - Nonalcoholic Steatohepatitis, NAS, Overweight or Obesity, Weight Loss, Bariatric Surgery Candidate
Interventions: Vertical Sleeve Gastrectomy (VSG); Procedure
Lead sponsor: University of Minnesota; Other
Eligibility: 40 Years to 67 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI
Interventions: Somatropin (DNA origin); Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 5 Years to 17 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: BG00011, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 40 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 21 more

Conditions: Internal Carotid Artery Stenosis, Cognitive Impairment
Interventions: Revascularization, Intensive Medical Management (IMM) alone; Procedure · Other
Lead sponsor: Columbia University; Other
Eligibility: 35 Years to 86 Years
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 56
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 45 more

Conditions: Aortic Stenosis, Aortic Stenosis, Severe
Interventions: Edwards SAPIEN 3/SAPIEN 3 Ultra THV; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: Not listed
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2038
U.S. locations: 50
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 43 more

Conditions: Healthy
Interventions: Placebo, Resistant Starch, Resistant starch + soluble fiber, Fiber made from corn starch, Fiber made from corn starch + soluble fiber; Dietary Supplement
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: QVA149, QAB149, NVA237, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 1,042 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 73
States / cities: Birmingham, Alabama • Montgomery, Alabama • Mesa, Arizona + 60 more

Conditions: Metastatic Cancer, Prostate Cancer
Interventions: atrasentan hydrochloride, docetaxel, prednisone, placebo; Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Male only
Enrollment: 1,038 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 554
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 378 more

Conditions: Emergency Contraception
Interventions: DR-104; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 11 Years to 16 Years · Female only
Enrollment: 343 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 5
States / cities: San Francisco, California • Atlanta, Georgia • Minneapolis, Minnesota + 2 more

Conditions: Covid19
Interventions: Ivermectin, Fluvoxamine, Fluticasone, Placebo, Montelukast, Metformin; Drug · Other
Lead sponsor: Susanna Naggie, MD; Other
Eligibility: 30 Years and older
Enrollment: 10,956 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 110
States / cities: Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more

Search by objective public record fields.

Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).

Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF)

Photobiomodulation Therapy and Nerve Density for Patients With Diabetic or Chemotherapy-associated Neuropathy

A Study of Disease Progression and Anti-HIV Treatments

Study of BIIB092 in Participants With Progressive Supranuclear Palsy

A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)

Study of Micafungin in Patients With Invasive Candidiasis or Candidemia

The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening

Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy

ST Segment Detection Study

Hepatic Energy Fluxes in NASH and NAS Patients

Clinical Trial of Growth Hormone in MPS I, II, and VI

An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis

Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial - Hemodynamics (CREST-H)

PARTNER 3 Trial - Aortic Valve-in-Valve

Satiety, Glycemic, and Gastrointestinal Effects of Novel Fibers

A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy

Emergency Contraception Actual Use Study

ACTIV-6: COVID-19 Study of Repurposed Medications